Search…

Shanghai Pharmaceuticals: Notification of Approval for Clinical Trial of New Indication B019

30/07/2025

Shanghai Pharmaceuticals announced on the evening of July 29th that its subsidiary Shangyu Biomedical Therapy's independently developed "B019" has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, allowing it to conduct clinical trials for refractory systemic lupus erythematosus.

Latest

3 m ago

The helicopter crash into the river in Germany has resulted in 2 deaths and 1 person missing.

4 m ago

The Colombian government has submitted the budget proposal for the year 2026 to Congress, with a budget size of 56 trillion pesos.

6 m ago

On Tuesday New York closing, the CME Bitcoin futures BTC main contract fell by 0.56% compared to Monday's New York closing, closing at $118,000. The CME Ethereum futures DCR main contract fell by 0.98%, closing at $3,785.50.

7 m ago

Visa executive: We believe that tariffs have not significantly affected cross-border payments.

7 m ago

Terida's net revenue in the second quarter was $6.52 billion, slightly exceeding the analyst's expectation of $6.509 billion. The adjusted EPS for the second quarter was $0.57, surpassing the analyst's forecast of $0.54. The revenue for the third quarter is expected to be between $7.10 billion and $7.70 billion, while analysts predicted $7.575 billion. The adjusted EPS for the third quarter is estimated to be between $0.69 and $0.87, lower than the analyst's expectation of $0.89. Terida's stock initially dropped more than 0.3% in after-hours trading, but later rose by 4.14%.

See all latest